MeiraGTx stock falls 5.96 percent as earnings beat estimates
Published on 09/25/2026 at 08:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
MeiraGTx stock fell 5.96 percent to a closing price of USD 11.05 on Nasdaq on September 24, 2026. The move followed a week that also brought a board appointment and fresh analyst coverage for the clinical-stage genetic medicines company.
Board appointment adds experience
MeiraGTx appointed healthcare portfolio manager Alan M. Sebulsky as a Class I director effective September 23, 2026, according to Yahoo Finance. His term runs through the company annual meeting in 2028, and he will serve on the Science and Technology Committee.
The appointment gives MeiraGTx four late-stage clinical programs in the public narrative, including candidates targeting Parkinson's disease, radiation-induced xerostomia and inherited retinal disease. The company also operates internal manufacturing facilities for viral-vector medicines.
Q2 earnings beat consensus
For Q2 2026, revenue reached USD 321.43 million and diluted EPS was USD 1.71. MarketBeat reported that the EPS result exceeded consensus of a USD 0.46 loss by USD 2.17, creating the clearest quantified contrast in the current investor case.
Goldman Sachs initiated coverage on September 24, 2026, with a Neutral rating and a USD 16.00 price target, according to Investing.com. That assessment places clinical execution and the conversion of the pipeline into commercial products ahead of quarterly earnings volatility.
Stock stays below yearly high
MeiraGTx closed at USD 11.05 on Nasdaq on September 24, 2026, with a market capitalization of USD 1,023,334,975. The 52-week range was USD 6.62 to USD 15.35, leaving the stock 28.01 percent below its high.
MeiraGTx stock facts
- Company: MeiraGTx Holdings plc
- Ticker: MGTX
- Trading venue: Nasdaq Global Select Market
- Closing price (September 24, 2026): USD 11.05
- Market capitalization: USD 1,023,334,975 (as of September 24, 2026)
- 52-week range: USD 6.62-15.35 (as of September 24, 2026)
- Sector / Industry: Healthcare / Biotechnology
